Bli medlem
Bli medlem

Du är här

2015-12-03

Camurus AB: Final price in Camurus's initial public offering set at SEK 57 per share - trading on Nasdaq Stockholm commences today

NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY,
IN OR INTO THE UNITED STATES OF AMERICA, CANADA, JAPAN, AUSTRALIA, OR
ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE
SUBJECT TO LEGAL RESTRICTIONS

Lund - 3 December 2015 -Camurus AB (publ) ("Camurus" or "Company")
hereby announces the outcome relating to the offering of newly issued
shares and sale of existing shares in the Company ("Offering") and
listing on Nasdaq Stockholm. The Offering attracted strong interest
among both Swedish and international investors.

The Offering in brief

· The final price of the Offering has been set at SEK 57 per share,
resulting in a market capitalization of Camurus of SEK 2,125 million.

· The Offering comprises in total 11,142,554 shares in Camurus,
corresponding to 30 percent of the total number of shares in the
Company, of which 9,736,842 shares are newly issued and 1,405,712
existing shares are offered by Sandberg Development AB ("Sandberg
Development" or the "Principal Shareholder") which the Principal
Shareholder acquired in direct conjunction with the Offering as part
of the completion of the Company's share bonus program.

· Furthermore, the Principal Shareholder has issued an
over-allotment option of up to 1,671,383 existing shares. If the
over-allotment option is fully utilised, the Offering will comprise
12,813,937 shares in total, corresponding to a total value of the
Offering of SEK 730 million, of which the gross proceed from the new
issue amounts to approximately SEK 555 million before deduction of
expenses relating to the Offering.

· Backahill Utveckling AB, Catella Fondförvaltning AB, the Fourth
Swedish National Pension Fund, Gladiator and Grenspecialisten
Förvaltning AB, have undertaken to acquire shares in the Offering
corresponding to SEK 240 million in total. Their shareholdings will,
in aggregate, amount to approximately 11 percent of the total number
of shares in the Company after the Offering.

· Following completion of the Offering, Sandberg Development will
remain the largest shareholder in Camurus and will, assuming that the
over-allotment option is exercised in full, hold approximately 54
percent of the total number of shares in the Company.

· All investors who have applied for acquisition of shares within
the Offering to the general public in Sweden have been allocated
shares.

· Trading of the Company's shares on Nasdaq Stockholm commences
today 3 December 2015 under the ticker "CAMX".

Fredrik Tiberg, President & CEO, comments:
"Camurus listing is an important step in the building of a strong and
viable pharmaceutical company based in Sweden. The IPO increases our
research and development capacity and enables future product launches
through the establishment of an own European commercial organisation,
initially focused on the opioid dependence market. The commitment
from cornerstone investors along with the broad interest from both
institutions and the general public are very encouraging and confirm
our strategy and future potential."

Carnegie Investment Bank and Handelsbanken Capital Markets are acting
as Joint Global Coordinators and Joint Bookrunners in the Offering.
Mannheimer Swartling Advokatbyrå is legal advisor to Camurus and the
Principal Shareholder. Gernandt & Danielsson Advokatbyrå KB is legal
adviser to the Joint Global Coordinators and Joint Bookrunners.

About Camurus

Camurus is a Swedish research-based pharmaceutical company committed
to developing and commercialising innovative and differentiated
medicines for the treatment of severe and chronic conditions. New
drug products with best-in-class potential are conceived based on the
proprietary FluidCrystal® drug delivery technologies and an extensive
R&D expertise. Camurus' clinical pipeline includes products for
treatment of cancer, endocrine diseases, pain and addiction,
developed in-house and in collaboration with international
pharmaceutical companies. For more information, visit
www.camurus.com.

For more information

Fredrik Tiberg, CEO and Head of Research
Tel. +46 (0)46 286 46 92
fredrik.tiberg@camurus.com

Rein Piir, VP Investor Relations
Tel. +46 (0)70 853 72 92
ir@camurus.com

Important information
This press release may not be distributed in or into the United
States, Canada, Japan, Australia or any other jurisdiction where such
action is wholly or partially subject to legal restrictions or where
such action would require additional prospectuses, registrations or
other actions in addition to what follows from Swedish law. Nor may
the information in this press release be forwarded, reproduced or
disclosed in a manner that contravenes such restrictions or would
entail such requirements.

In any EEA Member State, other than Sweden, that has implemented
Directive 2003/71/EC as amended (together with any applicable
implementing measures in any member State, the "Prospectus
Directive"), this press release is only addressed to and is only
directed at qualified investors in that Member State within the
meaning of the Prospectus Directive.

This press release and the information contained herein are not for
distribution in or into the United States. Any securities referred to
herein have not been and will not be registered under the U.S.
Securities Act of 1933, as amended (the "Securities Act"), and may
not be offered or sold in the United States absent registration or an
exemption from registration under the Securities Act. There is no
intention to register any securities referred to herein in the United
States or to make a public offering of the securities in the United
States. Any offering of securities mentioned herein in the United
States will be made only to a limited number of investors who are
deemed to be qualified institutional buyers as defined in Rule 144A
under the Securities Act ("QIBs") or pursuant to another available
exemption from, or transaction not subject to, the registration
requirements under the Securities Act.

In the United Kingdom, this press release and any other materials in
relation to the securities described herein is only being distributed
to, and is only directed at, and any investment or investment
activity to which this press release relates is available only to,
and will be engaged in only with, "qualified investors" (as defined
in section 86(7) of the Financial Services and Markets Act 2000) and
who are (i) persons having professional experience in matters
relating to investments who fall within the definition of "investment
professionals" in Article 19(5) of the Financial Services and Markets
Act 2000 (Financial Promotion) Order 2005 (the "Order"); or (ii) high
net worth entities falling within Article 49(2)(a) to (d) of the
Order (all such persons together being referred to as "relevant
persons"). Persons who are not relevant persons should not take any
action on the basis of this press release and should not act or rely
on it.

This press release may contain forward-looking statements which
reflect Camurus' current view on future events and financial and
operational development. Words such as "intend", "assess", "expect",
"may", "plan", "believe", "estimate" and other expressions which
imply indications or predictions of future development or trends, and
which are not based on historical facts, are intended to identify
forward-looking statements. Forward-looking statements inherently
involve both known and unknown risks and uncertainties as they depend
on future events and circumstances. Forward-looking statements do not
guarantee future results or development and the actual outcome could
differ materially from the forward-looking statements.

A prospectus prepared in accordance with the Prospectus Directive was
published on 19 November 2015 and is, subject to certain
restrictions, available on the websites of Camurus (www.camurus.se),
Carnegie (www.carnegie.se) and Handelsbanken
(www.handelsbanken.se/investeringserbjudande).

The information in this press release is disclosed by Camurus AB in
accordance with the Swedish Securities Markets Act and/or the Swedish
Financial Instruments Trading Act. The information was submitted for
publication at 07.00 a.m. on 3 December 2015.

-----------------------------------------------------------
http://feed.ne.cision.com/client/waymaker1/WOLReleaseFile.aspx?id=333418...
http://mb.cision.com/Main/13456/9878225/452309.pdf

Författare SIX news

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.